Every Form 4 that Quest Diagnostics Inc. (DGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DGX filings page.
Quest Diagnostics Executive Vice President and CFO Sam Sam reported several equity-related transactions. On February 18, 2026, he received a grant of 18,303 non-qualified stock options with an exercise right to buy shares, which vest in three equal annual installments beginning on the first anniversary of the grant date. He also acquired 3,965 shares of common stock as an award of restricted stock units and disposed of 855 and 1,010 shares of common stock solely to cover tax withholding obligations arising from the vesting of restricted stock units, at prices of $210.01 and $206.99 per share. In addition, on January 28, 2026, he acquired 69 shares of common stock through a dividend reinvestment plan at $183.514 per share. Following these transactions, his directly held common stock position was reported as 27,841 shares, and he directly held 18,303 options.
Quest Diagnostics SVP & General Counsel Michael E. Prevoznik reported a mix of stock transactions. On February 19, 2026, he sold 1,111 shares of common stock in an open-market transaction at $204.83 per share, executed under a Rule 10b5-1 sales plan.
On February 18, 2026, he received a grant of 9,289 non-qualified stock options with an exercise right to buy shares, which vest in three equal annual installments beginning on the first anniversary of the grant. He also acquired 2,013 shares of common stock as an award of restricted stock units, while 301 shares at $210.01 and 347 shares at $206.99 of common stock were surrendered to cover tax withholding from vesting. In addition, 5,738 shares are held indirectly through company 401(k) and deferred compensation plans.
Quest Diagnostics CEO and President J. E. Davis reported equity compensation and related tax withholding transactions. Davis was granted 73,225 non-qualified stock options, which vest in three equal annual installments beginning on the first anniversary of the grant date. He also received 15,857 shares of common stock, representing an award of restricted stock units. To cover tax withholding obligations arising from the vesting of restricted stock units, 2,396 shares and 3,788 shares of common stock were disposed of back to the issuer at prices of $210.01 and $206.99 per share, respectively. After these transactions, Davis directly owned 130,153 shares of common stock and 73,225 stock options.
Quest Diagnostics executive Catherine T. Doherty, EVP, Regional Businesses, reported multiple equity transactions. On February 19, 2026, she completed an open-market sale of 1,433 shares of common stock at $204.83 per share under a Rule 10b5-1 sales plan, leaving 68,402 directly held shares.
On February 18, 2026, she received a grant of 13,514 non-qualified stock options at an exercise price of $0.00 per option, vesting in three equal annual installments beginning on the first anniversary of the grant date. She also acquired 2,928 shares of common stock as a restricted stock unit award, with related tax-withholding dispositions of 433 shares at $210.01 and 728 shares at $206.99. In addition, 4,503 shares are held indirectly through the company’s 401(k) and Supplemental Deferred Compensation Plan.
Quest Diagnostics senior vice president Karthik Kuppusamy reported multiple equity-related transactions. He received a grant of 9,853 non-qualified stock options and an award of 2,135 restricted stock units, both at no cost. Shares of common stock totaling 252 and 259 were disposed of to the issuer solely to cover tax withholding obligations from vesting restricted stock units. He also recorded a small acquisition of 16 common shares under Rule 16a-6 and reported indirect holdings through a 401(k) plan and a trust. The granted options vest in three equal annual installments beginning on the first anniversary of the grant date.
Quest Diagnostics senior vice president and chief commercial officer Mark E. Delaney reported multiple equity-related transactions. On February 18, 2026, he was granted a non-qualified stock option for 7,332 shares, which vests in three equal annual installments beginning on the first anniversary of the grant date. He also received 1,586 shares of common stock, which the footnotes describe as an award of restricted stock units. On the same date, 205 shares at $210.01 and 230 shares at $206.99 of common stock were disposed of back to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units. Separately, on January 28, 2026, he acquired 15 shares of common stock through a dividend reinvestment plan, which the rules allow to be reported later on Form 5 but he chose to report on this Form 4.
Quest Diagnostics SVP and Chief Accounting Officer Michael J. Deppe reported a mix of equity grants and related tax share withholdings. On February 18, 2026, he was granted a non‑qualified stock option covering 1,688 shares, which vests in three equal annual installments beginning on the first anniversary of the grant date.
He also received an award of 366 restricted stock units. To cover tax withholding from vesting RSUs, 83 shares of common stock at $210.01 and 99 shares at $206.99 were disposed of to the issuer. After these transactions, he directly owns 34,560 shares of common stock and holds 1,688 options, plus an additional 706 shares indirectly through the company’s 401(k) plan.
Quest Diagnostics director Wright Lassiter III reported acquiring 7 shares of common stock on January 28, 2026 at $183.51 per share. The filing states these shares were obtained through a broker-administered dividend reinvestment plan and are eligible for deferred reporting under Rule 16a-6, but were reported early on Form 4. Following this small acquisition, his directly held position increased to 9,057 shares, a figure that includes shares previously acquired via dividend reinvestment since his last Form 4 filing.
Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On January 28, 2026, he acquired 6 shares of common stock at $183.51 per share. Following this routine reinvestment, he directly owns 2,704 shares of Quest Diagnostics common stock. The transaction was eligible for later reporting on Form 5, but he chose to report it early on this Form 4.
Quest Diagnostics director Vicky B. Gregg reported a small automatic share acquisition. On January 28, 2026, she acquired 67 shares of common stock at $183.513 per share through a broker-administered dividend reinvestment plan, bringing her direct holdings to 17,104 shares. The transaction was voluntarily reported early on Form 4, even though it was eligible for deferred reporting on Form 5 under Rule 16a-6.
Quest Diagnostics EVP Catherine T. Doherty reported an option exercise and related share sales. On 02/13/2026 she exercised 26,165 non-qualified stock options at $112.17 per share, receiving the same number of common shares.
That day she sold 26,165 common shares in several open-market transactions at weighted average prices between $205.2072 and $209.1024, under a pre-established Rule 10b5-1 sales plan. After these transactions, she held 68,068 common shares directly and 4,503 shares indirectly through a 401(k)/deferred compensation plan.
Quest Diagnostics executive Patrick Plewman reported multiple stock transactions involving DGX shares. On January 28, 2026, he acquired 48 shares of common stock at $183.512 per share through a dividend reinvestment plan administered by his broker, bringing direct ownership to 15,381 shares.
On February 10, 2026, he exercised a non-qualified stock option for 5,662 shares of common stock at an exercise price of $121.805 per share and immediately sold 5,662 shares of common stock at $204 per share in an open-market transaction. After these transactions, he directly owned 15,381 shares of Quest Diagnostics common stock. The filing notes that the option exercise and sale were carried out under a pre-arranged Rule 10b5-1 sales plan.
Quest Diagnostics CEO and President James E. Davis reported an option exercise and related stock sales. On 11/25/2025, he exercised a non-qualified stock option to buy 55,093 shares of common stock at an exercise price of $95.795 per share, increasing his direct holdings to 175,573 shares immediately after the exercise.
That same day, he sold shares in several market transactions under a pre-arranged Rule 10b5-1 sales plan. These sales included 9,342 shares at a weighted average price of $191.5888, 41,004 shares at $192.2715, and 4,747 shares at $192.9717, each executed in multiple trades within disclosed price ranges. After these transactions, Davis directly owned 120,480 shares of Quest Diagnostics common stock, and the reported stock option grant showed 0 options remaining following the exercise.
Quest Diagnostics director reports small stock sale
A director of Quest Diagnostics Inc. reported selling 1,250 shares of common stock on 11/25/2025 at a price of $191.76 per share. This insider now directly owns 17,037 Quest Diagnostics shares after the transaction. The filing is a Form 4 submitted for board member Vicky B. Gregg, with the form signed by an attorney-in-fact.
Quest Diagnostics senior executive Mark E. Delaney, SVP & Chief Commercial Officer, reported stock option exercises and a share sale in Quest Diagnostics Inc. common stock. On 11/18/2025, he exercised 7,846 stock options at an exercise price of $144.47 per share and 100 stock options at $143.33 per share, acquiring the same number of Quest Diagnostics shares. On the same date, he sold 7,946 shares of common stock at a price of $187.35 per share. Following these transactions, he directly owned 7,530 shares of Quest Diagnostics common stock. The filing notes that the exercise and sale were carried out under a pre-arranged Rule 10b5-1 sales plan adopted by the reporting person.
Quest Diagnostics (DGX) CEO and President James E. Davis reported a disposition of common stock tied to equity compensation. On 11/05/2025, 7,143 shares were withheld and delivered to the issuer at $175.57 per share (Code F) to cover tax obligations arising from the vesting of restricted stock units. Following this tax withholding, Davis directly beneficially owned 120,480 shares.
Quest Diagnostics (DGX) disclosed an insider transaction by its Executive Vice President & CFO. On 10/21/2025, the officer acquired 68 shares of common stock at a price of $189.081 per share, reported as an acquisition through a dividend reinvestment plan. Following this transaction, the officer directly beneficially owns 25,741 shares. The filing also notes that dividend reinvestment plan shares are eligible for deferred reporting on Form 5 under Rule 16a-6, but the officer elected to report early on this Form 4.
Quest Diagnostics (DGX) reported an insider transaction by its SVP for Diagnostic Services. On 10/21/2025, the officer acquired 46 shares of common stock at $189.079, as noted in a footnote describing purchases via a dividend reinvestment plan eligible for deferred reporting under Rule 16a-6 but reported early. Following this, direct beneficial ownership stood at 15,333 shares.
Quest Diagnostics (DGX): A company officer reported an insider transaction on a Form 4. On 10/21/2025, the SVP, Clinical Solutions acquired 15 shares of common stock at $189.076 per share.
Following this transaction, the reporting person beneficially owns 8,379 shares directly, plus 358 shares indirectly through a trust and 1,635 shares indirectly via the Company’s 401(k) plan.
Per the footnotes, the 15 shares were acquired through a dividend reinvestment plan and are eligible for deferred reporting on Form 5 under Rule 16a-6; the reporting person chose to report them early.
Quest Diagnostics (DGX) director Gary M. Pfeiffer reported a sale of common stock. On 10/22/2025, he sold 1,482 shares at $182.40 per share, and reported 29,431 shares beneficially owned directly after the transaction.
The filing also records an intra-plan transfer on 10/23/2025 within the company’s Amended and Restated Deferred Compensation Plan for Directors. 4,413.284 phantom common stock units—payable in cash and representing an equivalent number of shares—were transferred from the company stock fund to another investment option at a listed price of $190.58.
Quest Diagnostics (DGX) reported an insider transaction by a director. On 10/21/2025, the director acquired 70 shares of common stock at $189.082 per share, as disclosed on a Form 4.
The filing states the shares were acquired through a dividend reinvestment plan administered by the broker and were eligible for deferred reporting on Form 5 under Rule 16a-6; the reporting person chose to report early here. Following the transaction, the director beneficially owns 18,287 shares, held directly.
Quest Diagnostics (DGX) reported an insider transaction on Form 4. SVP & Chief Commercial Officer Mark E. Delaney acquired 15 shares of common stock on 10/21/2025 at $189.077 per share via a dividend reinvestment plan. Following the transaction, he beneficially owns 7,530 shares, held directly. The filing notes the transaction is eligible for deferred reporting under Rule 16a-6 and was reported early.
Quest Diagnostics (DGX) director Robert B. Carter reported acquiring 6 shares of common stock on 10/21/2025 at $189.089 per share. The shares were obtained through a dividend reinvestment plan eligible for deferred reporting on Form 5 under Rule 16a-6; the transaction was reported early.
After this transaction, Carter beneficially owns 2,698 shares, held directly.
Director Timothy M. Ring reported a non‑derivative change related to deferred compensation in Quest Diagnostics (DGX). On 10/01/2025 he received an accrual of 233 phantom stock units under the company’s Amended and Restated Deferred Compensation Plan for Directors; these units convert to cash payable upon his termination of service as a director. The filing shows 17,036.495 phantom stock units credited in his deferred compensation account as of the transaction date, which includes units from dividend reinvestment transactions exempt from reporting. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025. No option exercises, cash purchases, or sales of common stock are reported in this filing.
Wright L. Lassiter III, a director of Quest Diagnostics Inc. (DGX), reported on Form 4 that on 10/01/2025 he received 157 phantom stock units under the company's deferred compensation plan for directors. These phantom units arose from elective deferrals of the director's cash compensation and are payable in cash when the reporting person leaves board service. The filing states the total phantom stock units accrued in his deferred compensation account as of the transaction date include dividend-reinvestment credits exempt from separate reporting. The Form 4 shows zero dollar price for the transaction and indicates indirect ownership treatment for the accrued units.